Skip to main content

Infectious Disease

Infectious Disease Research

Overview

COVID-19

The COVID-19 pandemic represents an unprecedented challenge for our hospitals and our community, with the state of Florida as one of the nation’s hotspots. As of August 14, 2020, more than 313,000 patients have been tested nationally across the AdventHealth enterprise. In Florida, AdventHealth has tested over 276,000 patients.

To meet the demands of COVID-19 treatment options and clinical trials, AdventHealth Research Institute has engaged operational teams in the inpatient and outpatient settings to include medical oversight by a Physician Principal Investigator with prior infectious disease experience. Clinical research coordinators, medical assistants, lab techs, and program management support round out these multidisciplinary collaborative teams. 

OUR CAPABILITIES

Our world-class team of researchers, clinical scientists and support staff is equipped to meet a wide array of research needs ranging from early-phase PoC/PoM trials to Phase I-III trials as well as RWE and HEOR.

Highlights include:

  • PIs with extensive research and publications experience
  • CDA execution within 24 hours
  • Access to local IRB with ability to use Central IRB
  • IRB approval completed within two weeks of submission
  • MSA to FPI turnaround of five days (COVID trials)
  • Remote monitoring with access to EHR
  • Clinical Research Coordinators with experience in most EDC systems
  • High staff retention rates of our Research Assistants and Nurses.

 

Contact Information

Infectious Disease Research Team
301 E Princeton Street, Orlando, Florida 32804

Featured Clinical Trials

ENSEMBLE

COVID-19 Vaccine

Icon for trial | ENSEMBLE

AdventHealth was selected to participate in Ensemble, a Phase 3 clinical trial of Janssen's (Johnson & Johnson) investigational COVID-19 vaccine. This is a single dose: participants receive an injection either of the ...

Meet the Team

Our Capabilities

To aid operations in the containment, mitigation, surge, and post-surge phases of the pandemic, AdventHealth developed the COVID-19 Pandemic Tracker, where all orders for COVID-19 tests and their results are curated in a big data server, allowing for near real-time reporting. AdventHealth collects data resulting from nasopharyngeal and saliva PCR testing, serology, and rapid antigen testing in our inpatient, outpatient, and ED facilities. COVID-19 testing volumes, positive patient census, and intervention utilization and outcomes are published every half hour on the Pandemic Tracker Microsoft PowerBI dashboard. Supplementary dashboards track COVID-19 patient demographic and clinical data, cohort unit capacity, lab turnaround times, supply chain, PPE and medication inventory and demand.

The AdventHealth Research Institute initiated a registry study in order to collect and disseminate clinical and laboratory data for research for all patients tested in the Central Florida Division. Soon to be expanded to the entire AdventHealth enterprise, the registry was developed under the IRB approved protocol named “Registry and Biorepository of COVID-19 for AdventHealth Enterprise” (RECOVER-19 - AdventHealth IRBNet # 1590483). This protocol can support feasibility queries and is approved for data collection for the next five years.

RECOVER-19 is a real-world data (RWD) registry that includes clinical data on all patients tested for Coronavirus Disease 2019 (COVID-19) (both positive and negative) at AdventHealth CFD beginning January 1, 2020. The registry includes zip codes; demographic information; all personal medical history; and COVID-19 encounter clinical information such as type of encounter, length of stay, presenting symptoms, outcome, medication history during all inpatient visits and post-discharge, all procedures and diagnoses, and approximately 80 selected labs.